MX2014006399A - Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca. - Google Patents

Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.

Info

Publication number
MX2014006399A
MX2014006399A MX2014006399A MX2014006399A MX2014006399A MX 2014006399 A MX2014006399 A MX 2014006399A MX 2014006399 A MX2014006399 A MX 2014006399A MX 2014006399 A MX2014006399 A MX 2014006399A MX 2014006399 A MX2014006399 A MX 2014006399A
Authority
MX
Mexico
Prior art keywords
treatment
dry eye
eye syndrome
cell
signal transduction
Prior art date
Application number
MX2014006399A
Other languages
English (en)
Inventor
Jean-Marc Combette
Catherine Deloche
Original Assignee
Xigen Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Inflammation Ltd filed Critical Xigen Inflammation Ltd
Publication of MX2014006399A publication Critical patent/MX2014006399A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con el uso de inhibidores de proteína quinasa y más específicamente con el uso de inhibidores de la quinasa amino-terminal de la proteína quinasa c-Jun, (poli-)péptidos del inhibidor de la JNK, péptidos quiméricos o ácidos nucleicos que codifican para los mismos, así como las composiciones farmacéuticas que contienen los mismos, para el tratamiento de la queratoconjuntivitis seca.
MX2014006399A 2011-11-30 2012-11-30 Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca. MX2014006399A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011006003 2011-11-30
PCT/EP2012/004952 WO2013079213A1 (en) 2011-11-30 2012-11-30 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
MX2014006399A true MX2014006399A (es) 2015-04-10

Family

ID=47324033

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006399A MX2014006399A (es) 2011-11-30 2012-11-30 Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.

Country Status (12)

Country Link
US (1) US20140309400A1 (es)
JP (1) JP2015500213A (es)
KR (1) KR20140099526A (es)
CN (1) CN104023736A (es)
AU (1) AU2012344299A1 (es)
BR (1) BR112014013041A2 (es)
CA (1) CA2855223A1 (es)
EA (1) EA201491062A1 (es)
IL (1) IL232699A0 (es)
MX (1) MX2014006399A (es)
SG (1) SG11201402347YA (es)
WO (1) WO2013079213A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP3262060B1 (en) * 2015-02-25 2019-12-25 MacKay Memorial Hospital Peptides for use in the prevention and treatment of dry eye
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
EP3313428A1 (en) * 2015-06-26 2018-05-02 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment
KR101690539B1 (ko) 2015-07-30 2016-12-29 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
BR112019024040A2 (pt) * 2017-05-17 2020-09-24 Yuyu Pharma, Inc. peptídeo e composição farmacêutica para tratamen-to de doenças oculares comprendendo o mesmo peptídeo como ingrediente ativo
US20200390729A1 (en) * 2017-12-04 2020-12-17 Laboratorios Salvat, S.A. Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
KR102429281B1 (ko) 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1994008598A1 (en) 1992-10-09 1994-04-28 Advanced Tissue Sciences, Inc. Liver reserve cells
ATE365808T1 (de) 1995-07-28 2007-07-15 Marie Curie Cancer Care Transportproteine und deren verwendungen
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2004026406A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP2285364B1 (en) * 2008-05-07 2015-01-21 The Regents of The University of California Therapeutic replenishment and enrichment of ocular surface lubrication

Also Published As

Publication number Publication date
CA2855223A1 (en) 2013-06-06
BR112014013041A2 (pt) 2019-09-24
AU2012344299A1 (en) 2014-05-29
IL232699A0 (en) 2014-07-31
CN104023736A (zh) 2014-09-03
WO2013079213A1 (en) 2013-06-06
JP2015500213A (ja) 2015-01-05
SG11201402347YA (en) 2014-06-27
EA201491062A1 (ru) 2014-10-30
KR20140099526A (ko) 2014-08-12
US20140309400A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
MX2014006399A (es) Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.
MX2016017308A (es) Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades.
UA98101C2 (ru) Пептидные ингибиторы пути трансдукции сигнала jnk, которые имеют способность проникать в клетку
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
MX365864B (es) Inhibidores de bromodominio biciclicos novedosos.
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MY162737A (en) 4-1bb binding molecules
MY167231A (en) Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same
MX2013013913A (es) Polipeptidos.
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
WO2015063747A3 (en) Peptide inhibitors of tead/yap-taz interaction
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
WO2011062962A3 (en) Smndelta7 degron: novel compositions and methods of use
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
EA201792608A2 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
WO2015197194A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
EA201171414A1 (ru) Ингибиторы белков семейства iap
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
PH12017502345A1 (en) Novel thrombin inhibitors
MX2010011055A (es) Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.
WO2010118286A3 (en) Benzimidazole modulators of h1 receptor and/or ns4b protein activity
WO2016055160A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases